Tesla Wipes Out New Content Marketing Unit, Fired All Team Members 
PUMA x Ottolinger Unveil Futuristic Collection Inspired by Motorsport and Sci-Fi 
US Supreme Court Signals Support for Starbucks in Landmark Labor Law Case 
Tesla Expands in Thailand: New Interest Rate Program and Land Acquisition Talks 
Airbus Recruits Former JetBlue CEO Robin Hayes to Lead North American Operations 
Rivian's Earth Day Special: $5,000 Off for Trading Gas Cars for Electric 
Apple Adds Eight Chinese Companies to Its Supply Chain After Axing Four 
How corporate involvement in psychedelic research could threaten public safety 
Hollys Brews Expansion with First Overseas Outlet in Japan in May 
Disney Entertainment CTO to Step Down and Move to PENN Entertainment 
The language of insolvency: why getting it wrong can harm struggling firms 
LG Energy Solution to Combat Infringement By Launching Licensing Business for Battery Patents 
Tesla Reveals Plans to Release New EVs Earlier Than Scheduled, to Introduce Cheaper Models 
Kroger and Albertsons Extend Store Sale to C&S by 166 Stores in Push for Merger Approval 
ADM’s Suspended CFO to Resign After Accounting Probe 
Crypto.com's Launch in South Korea Stalled by AML Regulatory Concerns, Postponement Announced 
Amazon to Introduce Air Delivery Service in Arizona via Drone 
REHOVOT, Israel and NEW YORK, Sept. 20, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference, taking place September 26, 2017 at the Sofitel Hotel New York.
| Presentation Details | |
| Date: | Tuesday, September 26 |
| Time: | 4:00pm Eastern Time |
| Location: | Track 3 - Orleans |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications. The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care. AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
